September 10, 2021

Mushroom Trips & Stock Tips | Midas Letter RAW ft VXTR, Kevin O Leary, MNMD, ORIG, Stonecastle

Did you know… Molecules with psychedelic properties have been used for medicinal purposes for centuries? Where psychedelic molecules come from? How they are made? How they’re now being studied by some of the world’s most respected scientists? And that in 2018, Johns Hopkins University published results that mushroom trips with psilocybin can treat smoking addiction? As we heard from Kevin O’Leary last week, psychedelics are very exciting for their prospects of helping mental health. This week on Midas Letter RAW we outline psychedelic benefits, the novel compounds being created to help patients, and provide our stock tips to navigate those facts.

We have three exclusive CEO interviews on deck this week:

Mind Medicine (MindMed) Inc (NASDAQ:MNMD, NEO:MMED) CEO Robert Barrow

MindMed is a clinical-stage psychedelic medicine biotech company that seeks to discover, develop, and deploy psychedelic-inspired medicines and therapies to address addiction and mental illness. The company is assembling a compelling drug development pipeline of innovative treatments based on psychedelic substances, including psilocybin, LSD, MDMA, DMT and an Ibogaine derivative, 18-MC. Robert Barrow recently took over the helm of the company, becoming the new CEO. Mr. Barrow brings vast experience in the psychedelic space, having previously played a central role in designing and executing several successful regulatory and drug development strategies. With MindMed’s massive balance sheet cash position of $157 million (as reported in its latest financials), the potential for its novel treatments in clinical trials looks promising.

Origin Therapeutics Holdings Inc (Proposed for CNSX:ORIG) CEO Alexander Somjen

Ever want to invest and gain exposure to psychedelic companies before they go public? Origin Therapeutics provides that opportunity. The company is an actively managed investment issuer focused on making equity investments in psychedelics-related companies to provide investors with diverse exposure to the sector. Origin uses a time-tested due diligence process to optimize its pipeline to filter out only the most lucrative opportunities. With the experience sitting on Origin’s management and board (for example, the founding shareholders and board members were founders and early investors of companies like Charlottes Web, MedReleaf, Cybin, Green Thumb, or ICC Labs), Origin can help its private companies by providing advisory or board positions.


Midas Letter is provided as a source of information only, and is in no way to be construed as investment advice. James West, the author and publisher of the Midas Letter, is not authorized to provide investor advice, and provides this information only to readers who are interested in knowing what he is investing in and how he reaches such decisions.

Investing in emerging public companies involves a high degree of risk and investors in such companies could lose all their money. Always consult a duly accredited investment professional in your jurisdiction prior to making any investment decision.

Midas Letter occasionally accepts fees for advertising and sponsorship from public companies featured on this site. James West and/or Midas Letter may also receive compensation from companies affiliated with companies featured on this site. James West and/or Midas Letter also invests in companies on this site and so readers should view all information on this site as biased.